8 completed, 1 terminated. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 8, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
Follow SARS-CoV2 Infection: new trials by email Literature Review of SARS-CoV2 Infection trials Research Report on SARS-CoV2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID stellate ganglion block with 0.5% bupivacaine - Post Acute COVID-19 Syndrome, Long COVID | Phase 1 | Completed | Jonathann Kuo, MD | 20 | 2023-01-03 | 2025-03-13 |
| Topical Antibacterial Agents for Prevention of COVID-19 Neosporin, Vaseline - COVID-19, SARS-CoV2 Infection | Phase 1 | Completed | Yale University | 67 | 2022-09-01 | 2023-10-03 |
| IMM-BCP-01 in Mild to Moderate COVID-19 IMM-BCP-01, Placebo - SARS-CoV2 Infection, COVID-19 | Phase 1 | Terminated | Immunome, Inc. | 9 | 2022-06-03 | 2024-09-26 |
| Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein HDT-301 - SARS-CoV2 Infection | Phase 1 | Completed | HDT Bio | 48 | 2022-01-24 | 2024-10-23 |
| Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol Ad5-triCoV/Mac, ChAd-triCoV/Mac - COVID-19, SARS-CoV2 Infection | Phase 1 | Completed | McMaster University | 36 | 2022-01-03 | 2025-07-17 |
| Efficacy of Ivermectin in COVID-19 Ivermectin, Placebo - Safety, SARS-CoV2 Infection | Phase 1 / Phase 2 | Completed | Bangkok Metropolitan Administration Medical College and Vajira Hospital | 72 | 2021-09-01 | 2021-12-15 |
| Effect of IMMUNEPOTENT-CRP on Serum Pro-Inflammatory Cytokines in Mild to Moderate COVID-19 IMMUNEPOTENT-CRP (I-CRP), Placebo Comparator - COVID-19, SARS-CoV2 Infection | Phase 1 / Phase 2 | Completed | Universidad Autonoma de Nuevo Leon | 80 | 2021-04-20 | 2024-11-08 |
| Nigella 5 in the Treatment of SARS COV2 (COVID-19) Nigella, Placebo - SARS-CoV2 Infection | Phase 1 | Completed | Hôpital Universitaire Sahloul | 500 | 2021-03-01 | 2022-02-21 |
| Sildenafil in COVID-19 Sildenafil, Placebo - Covid19, SARS-COV2 Infection | Phase 1 / Phase 2 | Completed | Universidad Nacional Andres Bello | 40 | 2020-08-19 | 2021-09-29 |
COVID-19 (9) · Adenoviridae Infections (1) · Autonomic Nervous System Diseases (1) · Cytokine Release Syndrome (1) · Dysautonomia like disorder (1) · Post-Acute COVID-19 Syndrome (1) · Respiratory Aspiration (1) · Shy-Drager Syndrome (1)
Coronaviridae Infections (9) · Coronavirus Infections (9) · Infections (9) · Lung Diseases (9) · Nidovirales Infections (9) · Pneumonia (9) · Pneumonia, Viral (9) · RNA Virus Infections (9) · Respiratory Tract Diseases (9) · Respiratory Tract Infections (9) · Virus Diseases (9) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Basal Ganglia Diseases (1) · Brain Diseases (1)
Bupivacaine (1) · IMM20184, IMM20190, and IMM20253 drug combination (1) · Ivermectin (1) · Nigella sativa oil (1) · Petrolatum (1) · Sildenafil Citrate (1) · bacitracin zinc, neomycin sulfate, polymyxin B, drug combination (1) · repRNA-CoV2S vaccine (1)
Bangkok Metropolitan Administration Medical College and Vajira Hospital (1) · HDT Bio (1) · Hôpital Universitaire Sahloul (1) · Immunome, Inc. (1) · Jonathann Kuo, MD (1) · McMaster University (1) · Universidad Autonoma de Nuevo Leon (1) · Universidad Nacional Andres Bello (1) · Yale University (1)
United States (4) · Canada (1) · Chile (1) · Mexico (1) · Thailand (1) · Tunisia (1)
Charles Dela Cruz, MD (1) · Cristina Rodriguez-Padilla, Ph.D. (1) · Felipe Martinez, MD, MSc (1) · Fiona M Smaill, MD (1) · Jonathann Kuo, MD (1) · Jose Manuel Vazquez-Guillen, Ph.D. (1) · Mario Santamarina, MD (1) · Rene Rodriguez-Gutierrez, Ph.D. (1) · Riadh Boukef, professor (1) · Steven G Reed, Ph.D (1) · Thananda Trakarnvanich, M.D. (1)